Nnyefe ọgwụ ezubere iche maka ọrịa kansa

Nnyefe ọgwụ ezubere iche maka ọrịa kansa na-achọ imeziwanye ọgwụgwọ ọgwụgwọ yana ibelata mmetụta ya site na ibuga ndị na-ahụ maka ọgwụgwọ kpọmkwem na mkpụrụ ndụ kansa, na-ebelata ikpughe na anụ ahụ dị mma. Usoro a na-eji usoro dị iche iche, gụnyere nanoparticles, antibodies, na peptides, iji họrọ mkpụrụ ndụ kansa na ịhapụ ọgwụ na saịtị etuto ahụ. Nzipu a lekwasịrị anya na-akwalite itinye uche na ọgwụ n'ime etuto ahụ, na-eduga na nsonaazụ ka mma yana belata nsí sistemu. Nnyefe ọgwụ ezubere iche maka ọrịa kansa. Ihe mgbaru ọsọ mbụ nke Nnyefe ọgwụ ezubere iche maka ọrịa kansa bụ iji bulie mmetụta ọgwụgwọ nke ọgwụ ike ka ọ na-ebelata mmetụta ha na-egbu egbu na sel ahụike. A na-enweta nke a site na ibuga ọgwụ ozugbo na saịtị tumor ma ọ bụ mkpụrụ ndụ kansa, na-ahụ na mmetụta ọgwụ ahụ gbadoro ụkwụ n'ebe kachasị mkpa. Na Shandong Baofa Cancer Research Institute, Anyị raara onwe anyị nye ịkwalite ubi a site na nyocha ọhụrụ na ngwa ụlọ ọgwụ. Gịnị mere e ji ebute nnyefe ọgwụ ọjọọ dị mkpa? Chemotherapy na-emekarị na-agụnye usoro nchịkwa nke ọgwụ, nke pụtara na ọgwụ na-ekesa n'ime ahụ dum. Nke a nwere ike ibute nsonaazụ dị egwu, dị ka ntutu isi, ọgbụgbọ, na igbochi usoro ahụ ji alụso ọrịa ọgụ, ebe ọgwụ chemotherapy na-emetụtakwa mkpụrụ ndụ ahụike. Nnyefe ọgwụ ezubere iche maka ọrịa kansa na-enye ọtụtụ isi uru: Mmetụta Mbelata: Site n'ilekwasị anya na mkpụrụ ndụ kansa kpọmkwem, a na-echekwa mkpụrụ ndụ ahụike, na-ebute mmetụta dị ntakịrị ma dị ntakịrị. Nrụpụta emelitere: Enwere ike ịnyefe ọkwa dị elu nke ọgwụ ahụ ozugbo na saịtị tumor, na-eme ka ọ dị irè. Nsonaazụ ndị ọrịa emelitere: Ịrụ ọrụ ka mma na mbelata mmetụta nwere ike ime ka ndụ dịkwuo mma yana ọnụ ọgụgụ nlanarị maka ndị ọrịa cancer. Imeri Mgbochi Ọgwụ: Nnyefe ezubere iche nwere ike inye aka imeri usoro mgbochi ọgwụ nke mkpụrụ ndụ kansa nwere ike ịmalite ka oge na-aga. Nnyefe ọgwụ ezubere iche maka ọrịa kansa, nke ọ bụla nwere usoro ya pụrụ iche maka ịchebe mkpụrụ ndụ kansa na-ahọrọ: Passive TargetingPassive targeting na-adabere na njirimara pụrụ iche nke anụ ahụ tumor, dị ka arịa ọbara na-agbapụta na mmiri na-adịghị mma nke lymphatic. Emebere nanoparticles iji jiri njirimara ndị a, na-agbakọta nke ọma na microenvironment tumor. A na-akpọkwa nke a mmetụta Enhanced Permeability and Retention (EPR) .Active TargetingActive targeting gụnyere imezi ndị na-ebu ọgwụ na ligands kpọmkwem, dị ka ọgwụ nje, peptides, ma ọ bụ aptamers, nke na-ejikọta na ndị na-anabata ihe na-ejupụta na mkpụrụ ndụ cancer. Mmekọrịta a na-eme ka mkpụrụ ndụ kansa nwee ike ịhọrọ ndị na-ebu ọgwụ. Usoro a gụnyere: Antibody-Drug Conjugates (ADCs) ADCs nwere mgbochi mgbochi nke na-amata kpọmkwem antigen metụtara tumor, jikọtara ya na ọgwụ cytotoxic nwere ike. Ozugbo ADC jikọtara ya na cell cancer, ọ na-abanye n'ime ya, a na-ahapụkwa ọgwụ ahụ n'ime cell, na-eduga na ọnwụ cell. Otu ihe atụ bụ Ado-Trastuzumab Emtansine (Kadcyla) nke na-elekwasị anya na mkpụrụ ndụ kansa ara nke HER2 dị mma [1].Mkpụrụ ndụ ndị na-anabata ọrịa cancer na-egosipụtakarị ụfọdụ ndị nabatara n'elu ha. Site na ijikọta ligands (molecules na-ejikọta na ndị na-anabata ndị a) na ndị na-ebu ọgwụ, ọ ga-ekwe omume ịgbado ọgwụ ahụ ozugbo na mkpụrụ ndụ kansa ndị a. Folate receptors na transferrin receptors bụ ihe a na-achọkarị [2].Stimuli-Responsive DeliveryStimuli-responsive Responsive Sistemu na-anabata ọgwụ na-emebere iji hapụ ọgwụ naanị mgbe ihe mkpali pụrụ iche dị na microenvironment tumor, dị ka mgbanwe pH, ọrụ enzyme, ma ọ bụ ikike redox. Nke a na-eme ka a mata na a na-ahapụ ọgwụ ahụ naanị na saịtị tumor, na-ebelata mmetụta ndị a na-atụghị anya ya. Ọmụmaatụ gụnyere iji pH-sensitive liposomes nke na-ahapụ ụgwọ ọrụ ha na gburugburu acidic nke etuto ahụ [3].Nanịparticles dị na nnyefe ọgwụ ezubere iche. Nnyefe ọgwụ ezubere iche maka ọrịa kansa. Enwere ike imezi ụmụ irighiri ihe ndị a, nke na-adịkarị site na 1 ruo 100 nanometer n'ịdị elu, ka ha buru ọgwụ ma họrọ ya nyefee ha na mkpụrụ ndụ kansa. A na-eji ụdị nanoparticles dị iche iche, nke ọ bụla nwere uru nke ya: Liposomes: Spherical vesicles mejupụtara lipid bilayers, liposomes nwere ike encapsulate ma hydrophilic na hydrophobic ọgwụ. Polymeric Nanoparticles: Emere ya site na polymers biodegradable, nanoparticles ndị a na-enye ntọhapụ ọgwụ na-achịkwa yana nkwụsi ike. ntụpọ Quantum: Semiconductor nanocrystals nwere ngwa anya pụrụ iche, ntụpọ quantum nwere ike iji maka onyonyo na nnyefe ọgwụ. Carbon Nanotubes: Ihe owuwu cylindrical mere nke carbon carbon, carbon nanotubes nwere ike ịrụ ọrụ site na iji ligands na ọgwụ ezubere iche. Nnyefe ọgwụ ezubere iche maka ọrịa kansa A na-eji usoro ọgwụgwọ eme ihe ugbu a ma ọ bụ na-etolite: Doxil/Caelyx: Liposomal doxorubicin, nke akwadoro maka ọgwụgwọ ọrịa cancer ovarian, sarcoma Kaposi, na multiple myeloma [4]. Nhazi nke liposomal ya na-ebelata cardiotoxicity ma e jiri ya tụnyere doxorubicin omenala. Abraxane: Albumin-bound paclitaxel, nke a na-eji maka ọgwụgwọ ọrịa kansa ara, ọrịa cancer akpa ume na-abụghị obere cell, na ọrịa cancer pancreatic [5]. Njikọ albumin na-eme ka ịnyefe ọgwụ na saịtị etuto ahụ. Ihe ịma aka na ntuziaka Ọdịnihu Mgbe Nnyefe ọgwụ ezubere iche maka ọrịa kansa nwere nnukwu nkwa, ọtụtụ ihe ịma aka ka dị: Ọdịiche nke Tumor: Mkpụrụ ndụ cancer n'ime ụbụrụ nwere ike igosipụta àgwà dị iche iche, na-eme ka o sie ike ịchọta sel niile nke ọma. Nguzogide ọgwụ: Mkpụrụ ndụ kansa nwere ike ịmalite iguzogide ọgwụgwọ ezubere iche ka oge na-aga. Ihe mgbochi nnyefe: Ịbịaru ebe akpụ ahụ nwere ike bụrụ ihe ịma aka n'ihi ihe mgbochi physiological, dịka mgbochi ọbara-ụbụrụ. Nhazi na nrụpụta: Ịmepụta usoro nnyefe ọgwụ ezubere iche n'ọtụtụ buru ibu nwere ike ịdị mgbagwoju anya ma dị oke ọnụ. Mgbalị nyocha nke ga-eme n'ọdịnihu na-elekwasị anya na: Ịmepụta atụmatụ atụmatụ ndị ọzọ dị mgbagwoju anya iji merie ụdị ọrịa tumor. Ijikọta usoro ọgwụgwọ ezubere iche na usoro ọgwụgwọ ndị ọzọ, dị ka immunotherapy. Ịmepụta usoro nnyefe ihe na-akpali akpali nke nwere ike ime mgbanwe na microenvironment tumor na-agbanwe. Ịkwalite scalability na ọnụ ahịa nke n'ichepụta usoro nnyefe ọgwụ ezubere iche. Ọrụ Shandong Baofa Cancer Research Institute Shandong Baofa Cancer Research Institute, anyị na-arụsi ọrụ ike na nyocha na mmepe nke akwụkwọ akụkọ Nnyefe ọgwụ ezubere iche maka ọrịa kansa usoro. Ndị otu anyị nke ndị ọkà mmụta sayensị na ndị dọkịta na-arụ ọrụ iji merie ihe ịma aka ndị a kpọtụrụ aha n'elu ma tụgharịa nchoputa nyocha na-ekwe nkwa n'ime ngwa ụlọ ọgwụ. Anyị kwenyere na Nnyefe ọgwụ ezubere iche maka ọrịa kansa bụ atụmatụ dị mkpa maka imeziwanye nsonaazụ ọgwụgwọ ọrịa kansa na ịkwalite ndụ ndụ maka ndị ọrịa kansa.Nkwubi okwuNnyefe ọgwụ ezubere iche maka ọrịa kansa na-anọchite anya ọganihu dị ịrịba ama na ọgwụgwọ ọrịa cancer, na-enye ikike iji melite nrụpụta yana belata mmetụta. Site n'ichebe mkpụrụ ndụ cancer na-ahọrọ, usoro ndị a nwere ike ịnyefe ọgwụ dị elu ozugbo na saịtị tumor, na-eduga na nsonaazụ ka mma maka ndị ọrịa. Ọ bụ ezie na ihe ịma aka ka dị, nchọpụta na-aga n'ihu na mbọ mmepe na-emepe ụzọ maka ọgwụgwọ ọrịa cancer dị irè na ahaziri onwe ya. National Cancer Institute - Antibody-Drug Conjugates Ezubere iche folate receptor maka ọgwụgwọ ọrịa kansa Liposomes pH-sensitive maka ọgwụgwọ ọrịa kansa. Ụlọ ọrụ ọgwụ na Europe - Doxil FDA - Abraxane Prescribing Information